Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
This newly indexed research record examines “Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide.” Use the linked PR Newswire publication to assess the study design, population, methods, findings and limitations; an indexed record alone should not be read as clinical guidance.
Open original source ↗Collected Nov 7, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.